Amsterdam-based Leyden Labs, a platform working to free people from the threat of respiratory viruses has raised $70M (approximately €68M) in funding.
Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback